Inscripta has developed a gene-editing technology that provides scalable digital genome engineering with unparalleled simplicity. Their technology creates cost-effective libraries of thousands of bespoke protein, pathway, or genome variants, each with specific and trackable mutations. This empowers researchers to design, engineer, assess, and monitor results effectively and efficiently.

Investors Include:

GoldenArc, Vertical Venture Partners, iGlobe Partners, Spruceview Capital Partners, OMX Ventures, D1 Capital Partners, Foresite Capital Management, Fidelity Management & Research, Morgan Stanley, Oak HC/FT, Korys Investments, Venrock, ND Capital, Spruce Capital Partners, Phoenix International Investments, Durable Capital Partners, Counterpoint Global, JS Capital Management, Jonathan Feldstein, Paladin Capital Group, T. Rowe Price.

Own Inscripta stock or options?

Get an instant valuation

Completely free
100% confidential & secure
Takes less than a minute

What company do you own stock or options in?

How many shares or options do you own?

100% private & secure